[Genetic Counselor]

The answer depends heavily on which genetic category applies to a family.

Sporadic Alzheimer’s disease (no known family history).
A first-degree relative, meaning a parent, sibling, or child, of someone with sporadic, late-onset Alzheimer’s disease faces a lifetime chance of about fifteen-to-thirty-nine-in-one-hundred, often quoted as roughly twenty-to-twenty-five-in-one-hundred, compared with about ten-in-one-hundred in the general population. This is an elevated risk but not a predictable, gene-by-gene inheritance pattern.

Late-onset familial Alzheimer’s disease (three or more affected relatives, onset after age sixty-five).
This form is thought to involve many genes interacting together rather than one dominant change. First-degree relatives face roughly one-and-a-half-to-two times the general population’s risk, or about fifteen-to-twenty-five-in-one-hundred over a lifetime. When both parents have had Alzheimer’s disease, the risk to their children is thought to be at least double the general population’s risk.

Early-onset familial Alzheimer’s disease (APP, PSEN1, or PSEN2).
This form follows autosomal dominant inheritance, meaning a change in just one of the two gene copies a person carries is enough to cause disease. Each child of an affected parent has a fifty-in-one-hundred, or one-in-two, chance of inheriting that same gene change. A few practical points matter here:
• Affected parents are often no longer living by the time of diagnosis. Because onset is typically in early adulthood and progression can be relatively fast, a parent who carried the gene change may have passed away before their child’s symptoms even began, which can make a family history look falsely reassuring.
• A “negative” family history is not proof. Reduced penetrance, meaning a gene carrier does not always show symptoms, along with early parental death or missed diagnoses, means an apparently clean family history cannot be fully trusted unless parents were specifically evaluated or tested.
• Siblings of an affected person remain at meaningful risk even if parents seem unaffected, because of the possibility that a parent carries the change without ever having shown symptoms.

Because the practical meaning of “risk” is so different across these three situations, meeting with a genetics professional to correctly classify a family’s situation is often the most useful first step before estimating a specific number.

[Genetic Counselor]

Genetically, it helps to think of Alzheimer’s disease risk as falling into three distinct categories, each behaving differently.

• APP, PSEN1, and PSEN2 — the early-onset, single-gene forms. A pathogenic variant in any one of these three genes causes early-onset familial Alzheimer’s disease, typically beginning in a person’s forties or fifties.

o APP accounts for about ten-to-fifteen-in-one-hundred cases of early-onset familial disease, with onset usually in the forties and fifties, occasionally into the sixties.
o PSEN1 is the most common cause, accounting for roughly twenty-to-seventy-in-one-hundred cases of early-onset familial disease, with onset usually in the forties or early fifties. This form tends to progress relatively quickly, over six to seven years, and is often accompanied by seizures, involuntary muscle jerks called myoclonus, and language difficulties.
o PSEN2 is the least common of the three, accounting for about five-in-one-hundred cases, with a wider age range of onset, from forty to seventy-five. Some people with a PSEN2 change remain symptom-free even past age eighty, a pattern called reduced penetrance, meaning the gene change does not guarantee illness will appear.
o In twenty-to-forty-in-one-hundred families with a clear pattern of early-onset familial Alzheimer’s disease, no change in any of these three genes is found, meaning additional, not-yet-identified genes likely play a role.

• APOE — a risk-modifying gene, not a deterministic one. APOE comes in three common versions, called e2, e3, and e4. Carrying one or two copies of the e4 version raises the lifetime chance of developing Alzheimer’s disease but does not guarantee it happens, and does not follow the same predictable, single-gene inheritance as APP, PSEN1, or PSEN2. About forty-two-in-one-hundred people who develop Alzheimer’s disease do not carry an e4 variant at all, while the e2 version appears to offer some protection.

• Susceptibility genes. Roughly twenty other genes, including ABCA7, BIN1, CLU, and SORL1 among others, have each been linked to small increases in risk through large research studies. None of these causes Alzheimer’s disease on its own, and combining them into a “polygenic risk score” is not currently considered useful for individual clinical decision-making.

Because these categories behave so differently, understanding which one applies, or whether none does, is the foundation for any conversation about inheritance or testing.

[Genetic Counselor]

Alzheimer’s disease is a condition that slowly damages the brain, leading to memory loss and, over time, difficulty with thinking, judgment, and language. At the level of brain tissue, it involves a build-up of sticky protein clumps called amyloid plaques and twisted fibres called neurofibrillary tangles, which interfere with how brain cells communicate and survive. But the genetic picture behind that process looks quite different from one family to the next.

Most Alzheimer’s disease, roughly three-quarters of cases, is described as sporadic. This means it arises from a combination of aging, general genetic background, and other factors that are not yet fully understood, rather than from a single identifiable gene change. There is no clear inheritance pattern in these cases, and no single gene to blame.

About one-in-four cases are called familial, meaning three or more relatives in a family have had Alzheimer’s disease. Even here, most familial cases are not explained by one dominant gene. Instead, research suggests that many genes, each contributing a small amount of risk, act together with age and environment to produce the disease. Scientists have identified around twenty of these “susceptibility genes,” but no single variant in them is considered to cause Alzheimer’s disease on its own, and testing for them is not currently recommended as a diagnostic tool.

A distinctly different, smaller group is early-onset familial Alzheimer’s disease, making up fewer than two-in-one-hundred cases overall. This form is caused by a pathogenic variant, a disease-causing change, in one of three specific genes: APP, PSEN1, or PSEN2. Unlike sporadic or the broader familial form, changes in these three genes follow a clear, predictable, single-gene inheritance pattern.

One additional cause is worth knowing about: nearly everyone with Down syndrome develops the brain changes of Alzheimer’s disease after age forty. This happens because the APP gene sits on chromosome 21, and having three copies of that chromosome, as occurs in Down syndrome, leads to lifelong overproduction of the amyloid protein.

[Genetic Counselor]

Carrier screening is a type of genetic testing offered to people who are planning a pregnancy or who are already pregnant, with the goal of identifying whether they carry a genetic change, called a pathogenic variant, associated with a recessive genetic condition. Testing used in the course of reproductive counseling identifies typically healthy, symptom-free individuals who are heterozygous, meaning they carry one working copy and one non-working copy of a particular gene associated with an autosomal recessive or X-linked disorder.

For most autosomal recessive conditions, a person needs to inherit a non-working copy of a gene from both parents to be affected by the condition; a carrier, who has only one non-working copy, is generally healthy because their one working copy is enough for normal function. However, when two carriers of changes in the same gene have children together, each pregnancy carries a twenty-five percent chance that the child will inherit both non-working copies and be affected by the condition. Carrier screening also covers X-linked conditions, where the relevant gene is located on the X chromosome; here, a woman who carries a single non-working copy is usually unaffected or only mildly affected, but each of her sons has an increased chance of being significantly affected, since sons inherit only one X chromosome.

Carrier screening differs from diagnostic testing performed because a person or their family already shows signs of a genetic condition. Rather, it is a proactive, population-based or panel-based approach intended to inform reproductive decision-making before or during a pregnancy, well before any symptoms would ever be expected to appear, since carriers themselves are not affected by the conditions they carry.

It’s worth knowing that carrier screening is different from testing done because someone already has symptoms or a family history pointing to a specific condition. Carrier screening is done ahead of time, before any problem shows up, simply because carriers themselves never show symptoms.

[Genetic Counselor]

Current guidelines, from the American College of Medical Genetics and Genomics (2021), recommend offering this screening to everyone who is pregnant or planning a pregnancy — not just people with a family history or a specific ethnic background.
• Everyone who is pregnant or planning a pregnancy Should be offered a standard panel of tests, called Tier 3 screening. It covers 97 genes linked to recessive conditions and 16 genes linked to X-chromosome conditions. These genes were chosen because they cause moderate-to-severe conditions and are common enough to be worth checking. This applies to everyone, no matter their background.
• Partners The partner of a pregnant person can also be tested with the same panel, ideally at the same time. Testing both partners together makes the results easier to understand and act on.
• Best timing Testing before pregnancy gives the most time to think things through and consider every option. Testing during an existing pregnancy is still useful, but leaves fewer choices available.
• When more testing might be needed A doctor may suggest extra or wider testing if there’s a known genetic condition in the family, a family history that raises concern, or if the couple are blood relatives, such as second cousins or closer.
This approach of testing everyone regardless of their ancestry is fairly newer than older methods that only tested people from certain backgrounds. It’s meant to make sure everyone gets fair access to the same information.

[Genetic Counselor]

Carrier screening uses a simple blood sample. Most labs now use a technology called next-generation sequencing, which can check many genes at once, quickly and affordably. This is what has made it possible to test over a hundred genes in a single panel, instead of just one or two conditions at a time.
• Sequence analysis Reads through a gene, letter by letter, looking for changes that would stop it from working properly. This is the main method used for most genes on a carrier panel.
• Targeted variant analysis Checks only for a known, specific list of common changes. It’s used for some conditions, but full sequence analysis usually finds more, since it can pick up rarer changes too.
• Deletion or duplication analysis Looks for larger missing or extra pieces of a gene, rather than small letter-by-letter changes. Some genes need this kind of test to be checked properly.

A negative result lowers the chance that you carry a problem in that gene, but it can’t rule it out completely, no test catches every possible change, so a small “leftover” chance always remains. This is called residual risk, and it depends on the gene, the test method, and sometimes your background. A positive result means you’re a carrier of a specific condition. This is not a health concern for you, but it matters a lot for planning a pregnancy, especially if your partner turns out to be a carrier of a change in the same gene. Because these results can be a lot to take in, it’s best to go over them with a genetic counselor or geneticist, who can explain exactly what your result means and what to do next.

[Genetic Counselor]

Being identified as a carrier is common; most people carry at least one pathogenic variant for some recessive condition, and this is not expected to affect the carrier’s own health. The more significant question is what happens when both members of a couple are found to be carriers for changes in the same gene, since this substantially raises the chance of having an affected child.

• Autosomal recessive conditions When both partners are carriers of changes in the same gene, each pregnancy they conceive together has a twenty-five percent chance that the child inherits both non-working copies and is affected, a fifty percent chance the child is an unaffected carrier like the parents, and a twenty-five percent chance the child inherits neither non-working copy.
• X-linked conditions If a woman is found to be a carrier, each son has an increased chance of being significantly affected and each daughter has an increased chance of also being a carrier; the exact chances depend on the specific condition and inheritance pattern involved.
• Genetic counseling Couples identified as being at increased risk together are typically referred for genetic counseling, where the specific condition, its severity, its variability, and the accuracy of the test results can be discussed in detail.
• Reproductive options May include prenatal diagnostic testing during a pregnancy, such as chorionic villus sampling or amniocentesis, to determine whether a particular pregnancy is affected; preimplantation genetic testing performed on embryos created through in vitro fertilization, allowing selection of embryos that have not inherited both non-working copies; use of a donor egg or sperm; adoption; or proceeding with pregnancy while being prepared, through knowledge gained from testing, for the possibility of an affected child.
• Informed decision-making Differences in perspective, both among medical professionals and within families, exist regarding the use of these various reproductive options, and most healthcare professionals consider the choice among them to be a personal decision best made by the couple themselves after full discussion of the relevant facts.

[Genetic Counselor]

Carrier screening offers meaningful benefits but also carries limitations that are important for patients to understand before testing.
• Benefits Include the opportunity to learn about reproductive risk before or early in a pregnancy, time to consider the full range of reproductive options, the ability to plan for specialized prenatal or newborn care if a pregnancy is found to be affected, and reduced anxiety for the large majority of people who are found not to carry changes in the genes tested.
• Limitations Include the fact that no panel tests for every possible genetic condition, meaning a negative result does not guarantee an unaffected child; the existence of residual risk even for genes that are tested, since not every possible pathogenic variant is detectable by current technology; and the possibility of complex or uncertain results, such as a variant of uncertain significance, where it is not yet clear whether a particular genetic change is disease-causing.
• Panel size and content Vary between laboratories; while many laboratories follow the standardized Tier 3 panel, others offer larger panels including additional, rarer genes, referred to as Tier 4, or smaller panels. Discussing exactly which conditions a specific panel covers is a useful part of pre-test counseling.
• Psychosocial and ethical considerations Also arise, since carrier screening results can affect family planning decisions, relationships between partners, and, for some conditions, raise complex questions about disability and quality of life that different individuals and communities may view differently.
• Pre-test and post-test counseling Recommended for all patients undergoing carrier screening, ideally with a genetic counselor or other qualified professional, to ensure that patients understand what is being tested, what results might mean, and what options exist depending on the outcome.

Because the field of carrier screening continues to evolve, with panel content, technology, and professional society recommendations updated periodically, patients are encouraged to discuss the most current recommendations with their own care team at the time testing is considered.

[Genetic Counselor]

Predictive testing is generally structured as a multi-step process rather than a single blood draw, reflecting the significant, and permanent, nature of the information involved.

• Initial consultation: A genetic counselor or clinical geneticist reviews the family’s history, confirms the exact genetic change being tested for, and explains what is known about the condition, including its typical age of onset, range of severity, and whether preventive or treatment options exist.
• Psychological and practical assessment: This conversation explores the person’s reasons for seeking testing, their support network, and how they anticipate coping with either a positive or a negative result, and gives the person the opportunity to ask questions or decide not to proceed.
• Informed consent and sample collection: Once the person feels ready, they provide informed consent and a blood or saliva sample is collected and sent to a laboratory equipped to test specifically for the known familial genetic change.
• Result disclosure: Results are typically given in person or through a scheduled conversation, rather than by letter or an unscheduled phone call, so that a genetic counselor or physician can explain the result directly and address the person’s immediate reaction and questions.
• Follow-up support: Because emotional responses to results, in either direction, can continue to evolve for weeks or months, ongoing access to genetic counseling, and referral to mental health support or condition-specific patient support groups when appropriate, is considered part of good practice rather than an optional add-on.

For those who receive a positive result, the counseling team typically transitions the conversation toward condition-specific surveillance or management recommendations, as outlined for that particular disorder, and toward connecting the individual with any relevant specialists. For those who receive a negative result, counseling still has a role, since some individuals experience unexpected feelings of guilt or a sense of disconnection from affected family members, even amid relief.

[Genetic Counselor]

The use of predictive testing before birth or in childhood depends heavily on the specific condition involved, its age of onset, and whether earlier knowledge would change medical care, and these situations are approached differently from predictive testing in an at-risk adult.

• Prenatal testing refers to testing performed during an existing pregnancy to determine whether a fetus has inherited a familial genetic change, and is available once the causative variant is known in the family. This is a significant decision that is typically preceded by detailed genetic counseling covering the accuracy of the test, the meaning of possible results, and the range of options a person may consider in response to the results, and it remains entirely the choice of the pregnant individual.
• Preimplantation genetic testing is performed on embryos created through in vitro fertilization, before a pregnancy is established, and allows selection of embryos that have not inherited the familial genetic change, for those who wish to reduce transmission risk without facing decisions during an ongoing pregnancy.
• Predictive testing of minors, meaning children younger than eighteen who currently have no symptoms, is treated with particular caution by professional genetics organizations, including the National Society of Genetic Counselors, which generally recommends against predictive testing of asymptomatic minors for conditions that only begin causing symptoms in adulthood and for which no medical intervention would be started earlier as a result. This position is based on preserving the child’s own future right to decide, once they are old enough, whether they wish to know this information about themselves.
• Exceptions for childhood-onset conditions: When a condition can begin causing symptoms in childhood, or when starting surveillance or treatment early in childhood would meaningfully change outcomes, genetic testing in childhood is often appropriate and is handled through the same kind of careful counseling process used for affected individuals.

Families facing these situations are strongly encouraged to work with a clinical geneticist or genetic counselor familiar with the specific condition in their family, since the right approach differs considerably from one condition to the next.

[Genetic Counselor]

Predictive testing can offer meaningful benefits, but it also carries emotional, social, and practical considerations that are worth weighing carefully, which is why genetic counseling is built into the process rather than treated as optional.

Potential benefits:
• Resolution of uncertainty, since living with an unknown risk can itself be a source of chronic anxiety for some individuals, and a definitive result, in either direction, can allow more concrete planning.
• The opportunity to begin condition-specific surveillance or preventive treatment earlier than would otherwise happen, for conditions where early monitoring or intervention can meaningfully change outcomes.
• The ability to inform other at-risk relatives, so that they, too, can make their own informed decisions about testing.
• Reassurance for the substantial number of at-risk relatives whose test result turns out to be negative, who can then be released from intensive surveillance programs designed for higher-risk individuals.
• More informed family planning, including the option to consider prenatal testing, preimplantation genetic testing during fertility treatment, or the use of donor gametes, for those who wish to reduce the chance of passing a condition to their children. However, these options are not applicable for adult onset conditions.

Potential downsides:
• Psychological distress, which can include anxiety, depressive symptoms, or survivor guilt among family members who test negative, particularly in the period immediately following disclosure of results.
• Changes in family relationships and dynamics, since a result may reveal information about other relatives, including a parent’s own genetic status, that they had not previously known or chosen to learn.
• Possible impact on obtaining certain kinds of insurance, such as life, disability, or long-term care insurance, since legal protections against genetic discrimination vary by country and by insurance type and generally do not extend to every category of insurance.
• The emotional burden of “false reassurance” in some conditions, since a negative result for the known familial variant does not eliminate all future health risk from other, unrelated causes.
• The possibility that testing reveals unexpected information about family relationships, such as unrecognized non-paternity or non-maternity.

A genetic counseling session can help a person weigh these considerations against their own values and circumstances before a final decision to proceed is made.

[Genetic Counselor]

Predictive testing is offered to individuals who are biologically related to someone with a confirmed genetic diagnosis and who are therefore considered “at risk” based on the condition’s known inheritance pattern, most commonly a fifty percent risk for children, siblings, or parents of an affected person with an autosomal dominant or X-linked condition, though the exact risk depends on the specific relationship and inheritance pattern involved.

Before predictive testing takes place, several steps are generally recommended:
• Confirmation of the familial variant: The specific disease-causing genetic change must already be known from testing of an affected family member, since predictive testing in a healthy relative is only meaningful and accurate when it looks for that exact, previously identified change.
• Formal genetic counseling: A genetic counselor or clinical geneticist discusses the condition itself, the accuracy and limitations of the test, what a positive or negative result would and would not mean, and the emotional, family, and practical implications of proceeding, before any sample is collected.
• Assessment of readiness: Because the result cannot be undone once known, counseling sessions typically explore the person’s motivations for testing, their support system, and their plan for coping with either result, and testing is usually voluntary and can be paused or declined at any point in the process.
• Consideration of timing: Some individuals choose to delay testing until a particular life stage, such as before starting a family, while others prefer to test as soon as possible; there is no single correct timing, and this is a personal decision made in consultation with the counseling team.

Testing of asymptomatic individuals who are younger than eighteen years, for conditions that only cause symptoms in adulthood and for which no preventive medical action is available in childhood, is generally discouraged by professional genetics organizations, since the person cannot yet give their own informed consent and the timing offers no medical benefit to the child, exceptions are considered on a case-by-case basis when early knowledge would change medical management during childhood itself.

[Genetic Counselor]

Predictive genetic testing is genetic testing offered to a person who currently has no signs or symptoms of a particular inherited condition but who is known to be at increased risk of developing it, usually because a specific disease-causing genetic change has already been identified in a relative. The purpose of the test is to determine whether that same change is also present in the at-risk individual, which can clarify future health risk before any illness has appeared.

This is a meaningfully different situation from diagnostic testing, in which a person who already has signs or symptoms undergoes genetic testing to confirm or explain those findings. Because the person undergoing predictive testing is, by definition, healthy at the time of testing, the result carries a different kind of weight: rather than confirming an existing illness, it reshapes a person’s understanding of their future.

A few related terms are sometimes used, each with a slightly different meaning:
• Predictive testing generally refers to testing for conditions where a positive result does not guarantee that the condition will develop, or where the age of onset and severity cannot be precisely predicted, such as many adult-onset conditions with reduced penetrance.
• Presymptomatic testing is sometimes used interchangeably with predictive testing, though some sources reserve it for conditions where, in a person carrying the disease-causing change, the condition is essentially certain to eventually develop, such as Huntington disease.
• Carrier testing, by contrast, identifies whether a person carries a single copy of a genetic change for a condition that only causes disease when two copies are present, and does not by itself predict that person’s own future health.

Because predictive testing can only be performed once the specific genetic change responsible for the condition in that family has already been identified through testing of an affected relative, it is not typically the first step in a family’s genetic evaluation.

[Genetic Counselor]

The long-term outlook for Peutz-Jeghers syndrome is shaped mainly by two things: how effectively bowel complications from polyps are prevented in childhood and young adulthood, and how consistently cancer surveillance is followed throughout life. Individuals with this condition face a substantially increased lifetime risk of cancer compared to the general population, with one large combined analysis estimating an overall cancer risk of roughly eighty-three percent by age seventy. Cancers most associated with the condition include those of the colon and rectum, stomach, small bowel, breast, ovary, cervix, pancreas, uterus, testis, and lung, generally occurring at younger ages than in the general population. Because of this, lifelong surveillance starting in childhood and continuing throughout adult life is central to care.

• Digestive tract: colonoscopy and upper endoscopy beginning around age eight, together with small-bowel imaging by magnetic resonance enterography or video capsule endoscopy, repeated every one to three years in childhood and every two to three years in adulthood, with shorter intervals if polyps are found.
• Breast: clinical breast examination beginning around age eighteen, along with annual mammogram and breast magnetic resonance imaging beginning around age thirty.
• Gynaecologic: examination for early puberty beginning around age eight, followed by annual pelvic examination and cervical cytology, commonly called a Pap smear, beginning around age eighteen to twenty.
• Testicular: annual testicular examination and monitoring for early feminizing changes beginning around age ten, with ultrasound if clinically indicated.
• Pancreas: imaging with endoscopic ultrasound or magnetic resonance imaging, ideally at a center experienced in this condition, beginning around age thirty to thirty-five.
• Lung: no specific imaging schedule is currently recommended, but education about symptoms and support for smoking cessation are advised given the elevated risk.

Genetic counseling at the time of diagnosis, and again as children approach the age when surveillance would begin, helps families understand this schedule and plan accordingly. Because published guidance in this area continues to evolve as more is learned, families are encouraged to have this monitoring plan reviewed periodically with their care team.

[Genetic Counselor]

Currently, the best available treatment is symptomatic management, there is no complete cure for Peutz-Jeghers syndrome itself, so management focuses on removing polyps before they cause complications, catching cancers at their earliest and most treatable stage, and coordinating care across the many organ systems that can be affected. Care is generally best delivered by a team that includes a gastroenterologist, a geneticist or genetic counsellor, and, depending on findings, specialists in gynaecology, endocrinology, and oncology.

• Endoscopic polyp removal, called polypectomy, is the main treatment for polyps once they reach about one centimetre in size. Removing polyps at this stage reduces the risk of bleeding, obstruction, and intussusception, and may also lower the long-term cancer risk associated with these polyps.
• Small-bowel imaging and treatment techniques have advanced considerably in recent years. Video capsule endoscopy, in which a small-swallowed camera captures images as it passes through the digestive tract, is now generally preferred as the first-line method for detecting small-bowel polyps, with magnetic resonance enterorrhaphy as a reliable alternative that avoids radiation exposure. Balloon-assisted enteroscopy allows many polyps deep in the small bowel to be removed without open surgery, reserving surgical removal of bowel tissue for polyps that cannot be reached this way.
• Intussusception and malignancies, when they occur, are treated using standard surgical and oncologic approaches.
• Hormonal tumours, such as oestrogen-producing testicular tumours in boys, can sometimes be managed with medications called aromatase inhibitors, which can reduce breast tissue growth and slow accelerated bone growth if treatment is started before puberty is complete.
• Preventive surgery, such as removal of the breasts, ovaries, or uterus, is not yet supported by strong evidence specific to Peutz-Jeghers syndrome but may be considered on an individual basis in discussion with a specialist centre, taking family history and personal risk factors into account.

Because tobacco use appears to further increase the already elevated risk of certain cancers, including of the cervix, lung, and pancreas, smoking avoidance and cessation support are an important part of care. Research into medications that might reduce polyp formation, including certain anti-inflammatory drugs and cell-growth pathway inhibitors, is ongoing, though none has yet been established as a standard therapy.

[Author]

Posts